HKG: 2185

Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China

Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that China’s National Medical Products Administration (NMPA)...

Company Medical Device

Shanghai Bio-heart Secures Israeli Registration for Iberis RDN System – World’s Only Dual-Access Renal Denervation Platform

Fineline Cube Jun 10, 2026

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced it has received regulatory approval for...

Company Medical Device

Bio-heart Bio Expands Iberis RDN Registration to Thailand – World’s Only Dual‑Access Renal Denervation System

Fineline Cube Mar 18, 2026

Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis...

Medical Device

Bio-heart Secures Indonesia Approval for Iberis RDN System

Fineline Cube Jan 27, 2026

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its...

Medical Device

Bio-heart’s IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System

Fineline Cube Nov 27, 2025

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that its Iberis Multi-Electrode Renal Denervation...

Company Medical Device

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach

Fineline Cube Oct 31, 2025

Shanghai Bio‑Heart Biological Technology Co., Ltd. (HKG: 2185) announced that its subsidiary, Shanghai AngioCare Medical...

Company Medical Device

Bio-heart Launches Iberis Renal Ablation System at OCC 2025

Fineline Cube Jun 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...

Company Medical Device

Shanghai Bio-heart Launches SAKURA-SCB Study for Drug-Coated Balloon in Japan

Fineline Cube Mar 31, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the first patient enrollment for...

Company Medical Device

Bio-heart’s Iberis RDN System Completes First Commercial Surgery in Germany

Fineline Cube Mar 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the successful completion of its...

Company Medical Device

Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment

Fineline Cube Feb 27, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced that its subsidiary, Shanghai Angiocare...

Company Medical Device

Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension

Fineline Cube Jul 3, 2023

China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...

Company Medical Device

Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study

Fineline Cube Apr 12, 2023

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...

Company Medical Device

Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France

Fineline Cube Mar 29, 2023

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment...

Company Medical Device

Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that it will initiate...

Company Medical Device

Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced receiving ethical approval from...

Company Deals

Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device

Fineline Cube Sep 6, 2022

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker,...

Company Deals

Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies

Fineline Cube Sep 6, 2022

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular...

Medical Device

Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds

Fineline Cube Aug 17, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for...

HKG: 2185

Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China

Shanghai Bio-heart Secures Israeli Registration for Iberis RDN System – World’s Only Dual-Access Renal Denervation Platform

Bio-heart Bio Expands Iberis RDN Registration to Thailand – World’s Only Dual‑Access Renal Denervation System

Bio-heart Secures Indonesia Approval for Iberis RDN System

Bio-heart’s IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach

Bio-heart Launches Iberis Renal Ablation System at OCC 2025

Shanghai Bio-heart Launches SAKURA-SCB Study for Drug-Coated Balloon in Japan

Bio-heart’s Iberis RDN System Completes First Commercial Surgery in Germany

Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment

Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension

Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study

Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France

Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan

Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan

Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device

Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies

Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds

You Missed

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China